Indication
Hyper-IgD periodic fever syndrome
Hyper-IgD periodic fever syndrome is a rare, autosomal recessive autoinflammatory disorder representing the milder phenotypic presentation of mevalonate kinase deficiency. Read more about Hyper-IgD periodic fever syndrome
3 drugs 2 manufacturers
Drugs that treat it
Common Hyper-IgD periodic fever syndrome therapies.
ILARIS (PF) (canakinumab/PF)
ILARIS (canakinumab/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHyper-IgD periodic fever syndrome is a rare, autosomal recessive autoinflammatory disorder representing the milder phenotypic presentation of mevalonate kinase deficiency.
Primarily manifesting during infancy or early childhood, the condition affects systemic innate immunity and is most frequently identified in individuals of Northern European descent.
It is pathophysiologically driven by loss-of-function variants in the *MVK* gene, which disrupt the mevalonate-cholesterol biosynthesis pathway and precipitate excessive, unprovoked interleukin-1–driven systemic inflammation.
Clinically, affected patients experience recurrent febrile episodes—frequently triggered by vaccinations, infection, or physiologic stress—lasting three to seven days and accompanied by painful cervical lymphadenopathy, abdominal pain, aphthous stomatitis, arthralgia, and cutaneous eruptions, alongside persistently elevated serum immunoglobulin D levels in most individuals.
- nih.gov
Hyper-IgD periodic fever syndrome is a rare, autosomal recessive autoinflammatory disorder representing the milder phenotypic presentation of mevalonate kinase deficiency
- knowrare.com
Hyper-IgD periodic fever syndrome is a rare, autosomal recessive autoinflammatory disorder representing the milder phenotypic presentation of mevalonate kinase deficiency
- medlineplus.gov
Primarily manifesting during infancy or early childhood, the condition affects systemic innate immunity and is most frequently identified in individuals of Northern European descent Clinically, affected patients experience recurrent febrile episodes—frequently triggered by vaccinations, infection, or physiologic stress—lasting three to seven days and accompanied by painful cervical lymphadenopathy, abdominal pain, aphthous stomatitis, arthralgia, and cutaneous eruptions, alongside persistently e...
- merckmanuals.com
Primarily manifesting during infancy or early childhood, the condition affects systemic innate immunity and is most frequently identified in individuals of Northern European descent It is pathophysiologically driven by loss-of-function variants in the *MVK* gene, which disrupt the mevalonate-cholesterol biosynthesis pathway and precipitate excessive, unprovoked interleukin-1–driven systemic inflammation Clinically, affected patients experience recurrent febrile episodes—frequently triggered by v...
- dermnetnz.org
It is pathophysiologically driven by loss-of-function variants in the *MVK* gene, which disrupt the mevalonate-cholesterol biosynthesis pathway and precipitate excessive, unprovoked interleukin-1–driven systemic inflammation
- rheumatology.org
Clinically, affected patients experience recurrent febrile episodes—frequently triggered by vaccinations, infection, or physiologic stress—lasting three to seven days and accompanied by painful cervical lymphadenopathy, abdominal pain, aphthous stomatitis, arthralgia, and cutaneous eruptions, alongside persistently elevated serum immunoglobulin D levels in most individuals
Personalize your experience
Follow Hyper-IgD periodic fever syndrome and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.